Navigating The Complexities Of An IND Submission In The Emerging Chinese Market

Source: Lonza

While China’s pharmaceutical market is growing at a steady pace, the drug registration timeline and process has been notoriously complex and lengthy, leading to a severe backlog of investigational new drug (IND) application submissions and an average delay as long as 14 months to register a clinical trial for an innovative drug.1 These challenges, combined with a focus on driving new drug innovation in China, led to efforts in 2015 to amend and reform the review and approval system for drugs and medical devices in China as well as improve drug quality.2


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online